Original Research
Published on 03 Feb 2026
Luteolin mitigates proliferative vitreoretinopathy through inhibition of ERK1/2 signaling and epithelial–mesenchymal transition
in Experimental Pharmacology and Drug Discovery
- 216 views
Original Research
Published on 03 Feb 2026
in Experimental Pharmacology and Drug Discovery
Case Report
Published on 03 Feb 2026
in Surgical Oncology
Original Research
Published on 03 Feb 2026
in Connected Health
Correction
Published on 03 Feb 2026
in Food Microbiology
Correction
Published on 03 Feb 2026
in Agricultural and Food Economics
Correction
Published on 03 Feb 2026
in Inflammation
Review
Published on 03 Feb 2026
in Neuro-Otology
Review
Published on 03 Feb 2026
in Diabetes: Molecular Mechanisms
Systematic Review
Published on 03 Feb 2026
in Higher Education
Editorial
Published on 03 Feb 2026
Correction
Published on 03 Feb 2026
in Coastal Ocean Processes
Frontiers in Science Editorial
Published on 03 Feb 2026
Review
Published on 03 Feb 2026
in Vaccines and Molecular Therapeutics
Original Research
Published on 03 Feb 2026
in Plant Breeding
Editorial
Published on 03 Feb 2026
in Precision Medicine
Original Research
Published on 03 Feb 2026
in Sustainable and Intelligent Phytoprotection